Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis

Hippokratia

Volumn 12, Issue 3, 2008, Pages 132-138

  Paschos, K A ^a   Bird, N ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Ablation; Chemotherapy; Colorectal cancer; Liver metastasectomy; Liver metastasis

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOXORUBICIN; FLOXURIDINE; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; GADOLINIUM; IODINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; HUMAN; LABORATORY; LAPAROSCOPY; LIVER METASTASIS; LIVER SURGERY; LOW LEVEL LASER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT CONTRAINDICATION;

EID: 46949083213     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathological basis of disease, 7th ed, Philadelphia: Elsevier Saunders; 2005; p. 269-343
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488
3. Rothbarth J, van de Velde CJ. Treatment of liver metastases of colorectal cancer. Ann Oncol 2005; 16 (Suppl 2): ii144-ii149
4. McMillan DC, McArdle CS. Epidemiology of colorectal liver metastases. Surg Oncol 2007; 16: 3-5
5. Cancerstats. Cancer Research UK 2005
6. Al-Asfoor A, Fedorowicz Z. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane database of Syst Rev (Online) 2007; 4: CD006039
7. Debois JM. TxNxM1: the anatomy and clinics of metastatic cancer: Boston Kluwer Academic Publishers; 2002; p. 62-63
8. Ottmar MD, Gonda RL Jr, Leithauser KJ, Gutierrez OH. Liver function tests in patients with computed tomography demonstrated hepatic metastases. Gastrointest Radiol 1989; 14: 55-58
9. Mielczarek M, Chrzanowska A, Scibior D, et al. Arginase as a useful factor for the diagnosis of colorectal cancer liver metastases. Int J Biol Markers 2006; 21: 40-44
10. Morris KT, Song TJ, Fong Y. Recent advancements in diagnosis and treatment of metastatic colorectal cancer to the liver. Surg Oncol 2006; 15: 129-134
11. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 2005; 5 Spec No A: S149-S156
12. Bipat S, van Leeuwen MS, Ijzermans JN, et al. Evidence-base guideline on management of colorectal liver metastases in the Netherlands. Neth J M 2007; 65: 5-14
13. Sarikaya I, Bloomston M, Povoski SP, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 2007; 5: 64
14. Vogel WV, Wiering B, Corstens FH, Ruers TJ, Oyen WJ. Colorectal cancer: the role of PET/CT in recurrence. Cancer Imaging 2005; 5 Spec No A: S143-S149
15. McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: current perspectives. Cancer Control 2006; 13: 32-41
16. Garden OJ, Rees M, Poston GJ, et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55 (Suppl 3): iii1-iii8
17. Metcalfe MS, Bridgewater FH, Mullin EJ, Maddern GJ. Useless and dangerous-fne needle aspiration of hepatic colorectal metastases. BMJ 2004; 328(7438): 507-508
18. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for meta-static colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318
19. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 2007; 246: 183-191
20. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-1262
21. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189: 291-299
22. Khatri VP, Chee KG, Petrelli NJ. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol 2007; 16: 71-83
23. Jaeck D, Nakano H, Bachellier P, et al. Signifcance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002; 9: 430-438
24. Jaeck D. The signifcance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol 2003; 10: 1007-1011
25. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. Arch Surg 1992; 127: 1403-1406
26. Friedel G, Pastorino U, Buyse M, et al. Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases-the International Registry of Lung Metastases. Zentralbl Chir 1999; 124: 96-103
27. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005; 12: 900-909
28. Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003; 197: 233-241
29. Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG, Nagorney DM. Concurrent vs staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Col Rectum 2004; 47: 1310-1316
30. Moug SJ, Horgan PG. The role of synchronous procedures in the treatment of colorectal liver metastases. Surg Oncol 2007; 16: 53-58
31. Minagawa M, Makuuchi M, Torzilli G, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231: 487-499
32. Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for multiple colorectal metastases: infuence of parenchymal involvement and total tumor volume vs number or location, on long-term survival. Arch Surg 2002; 137: 1187-1192
33. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14 (Suppl 2): ii13-ii1
34. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232: 777-785
35. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004; 240: 1037-1049
36. Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003; 238: 871-883
37. Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg 2003; 20: 481-496
38. Metcalfe MS, Mullin EJ, Maddern GJ. Choice of surveillance after hepatectomy for colorectal metastases. Arch Surg 2004; 139: 749-754
39. Leen E, Horgan PG. Radiofrequency ablation of colorectal liver metastases. Surg Oncol 2007; 16: 47-51
40. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451
41. Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 2000; 232: 665-672
42. Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999; 86: 784-788
43. Ackerman NB. The blood supply of experimental liver metastases. IV Changes in vascularity with increasing tumor growth. Surgery 1974; 75: 589-596
44. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 2003; 8: 553-566
45. Homsi J, Garrett CR. Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. Cancer Control 2006; 13: 42-47
46. Kemeny NE ND, Hollis DR, et al. Final analysis of hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a CALGB randomized trial of effcacy, quality of life (QOL), cost effectiveness, and molecular markers. American Society of Clinical Oncology Gastrointestinal Cancers Symposium Hollywood, 2005
47. Meta Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Nat Cancer Instit 1996; 88: 252-258
48. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78: 1639-1645
49. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129: 176-187
50. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520
51. Wein A, Riedel C, Bruckl W, et al. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003; 64: 131-138
52. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fuorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243-9249
53. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist 2007; 12: 825-839
54. Kelly C, Cassidy J. Chemotherapy in metastatic colorectal cancer. Surg Oncol 2007; 16: 65-70
55. Abeloff M AJ, Niederhuber J, Kastan M, Mc Kenna M. Clinical Oncology. Liver metastasis. 3rd ed: Elsevier Churchill Livingstone 2004; 1141-1171
56. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fuorouracil compared with fuorouracil alone as frst-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
57. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fuorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914
58. Gates VL, Atassi B, Lewandowski RJ, et al. Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors. Future Oncol 2007; 3: 73-81
59. Yin FF, Das S, Kirkpatrick J, Oldham M, Wang Z, Zhou SM. Physics and imaging for targeting of oligometastases. Semin Radiat Oncol 2006; 16: 85-101
60. Timmerman R, Papiez L, Suntharalingam M. Extracranial stereotactic radiation delivery: expansion of technology beyond the brain. Technol Cancer Res Treat 2003; 2: 153-160